Nektar Therapeutics
NEWS
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
With the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting ongoing, there are hundreds of newsworthy stories. Here is a few of our top picks so far.
It’s been a busy week for Nektar Therapeutics with the announcement of an NDA submission to the FDA for NKTR-181 and a non-exclusive, clinical collaboration deal with Syndax Pharmaceuticals.
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.
Wednesday was the big day for pharma and biotech companies to unveil abstracts ahead of the annual American Society of Oncology meeting in Chicago next month. Some companies have unveiled positive results that are making investors happy, while others… not so much.
Rumors of Nektar Therapeutics being up for sale may have been premature.
Nektar is reportedly exploring various strategic options, including a possible sale, partnerships or licensing agreements.
Immuno-oncology therapeutics have revolutionized certain types of cancer treatments, and they are, in many ways, as close to miracle cures as we’ve seen in decades.
Daiichi Sankyo informed Nektar that it was terminating a collaboration and licensing deal, effective Feb. 4, 2018.
JOBS
IN THE PRESS